JP2021529814A5 - - Google Patents
Info
- Publication number
- JP2021529814A5 JP2021529814A5 JP2021500661A JP2021500661A JP2021529814A5 JP 2021529814 A5 JP2021529814 A5 JP 2021529814A5 JP 2021500661 A JP2021500661 A JP 2021500661A JP 2021500661 A JP2021500661 A JP 2021500661A JP 2021529814 A5 JP2021529814 A5 JP 2021529814A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- cycloalkyl
- heterocycloalkyl
- alkyl
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695384P | 2018-07-09 | 2018-07-09 | |
| US62/695,384 | 2018-07-09 | ||
| PCT/IB2019/055811 WO2020012339A1 (en) | 2018-07-09 | 2019-07-08 | Chemical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021529814A JP2021529814A (ja) | 2021-11-04 |
| JP2021529814A5 true JP2021529814A5 (https=) | 2022-07-15 |
Family
ID=67997654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500661A Pending JP2021529814A (ja) | 2018-07-09 | 2019-07-08 | 化学化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210253528A1 (https=) |
| EP (1) | EP3820843A1 (https=) |
| JP (1) | JP2021529814A (https=) |
| CN (1) | CN112424167A (https=) |
| BR (1) | BR112021000332A2 (https=) |
| CA (1) | CA3105942A1 (https=) |
| WO (1) | WO2020012339A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118239937A (zh) | 2017-08-09 | 2024-06-25 | 戴纳立制药公司 | 化合物、组合物及方法 |
| DK3676297T3 (da) | 2017-09-01 | 2023-08-14 | Denali Therapeutics Inc | Forbindelser, sammensætninger og fremgangsmåder |
| US11939320B2 (en) | 2017-11-02 | 2024-03-26 | Abbvie Inc. | Modulators of the integrated stress pathway |
| WO2019118785A2 (en) | 2017-12-13 | 2019-06-20 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| WO2019236710A1 (en) | 2018-06-05 | 2019-12-12 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| TWI877863B (zh) | 2018-10-11 | 2025-03-21 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| US12091392B2 (en) | 2019-02-13 | 2024-09-17 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| MA54953A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| MX2021013197A (es) * | 2019-04-30 | 2022-02-24 | Calico Life Sciences Llc | Cicloalquilos sustituidos como moduladores de la vía integrada del estrés. |
| JP2022536663A (ja) | 2019-06-12 | 2022-08-18 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路のモジュレーター |
| MX2022011143A (es) | 2020-03-11 | 2022-10-13 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| US20230391763A1 (en) | 2020-10-22 | 2023-12-07 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| MX2023004623A (es) | 2020-10-22 | 2023-05-12 | Evotec Int Gmbh | Moduladores de la via integrada de respuesta al estres. |
| JP2023546224A (ja) | 2020-10-22 | 2023-11-01 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 統合ストレス応答経路のモジュレーター |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| BR0116452A (pt) | 2000-12-21 | 2003-09-30 | Glaxo Group Ltd | Composto, composição farmacêutica, uso de um composto |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| EP1525185A1 (en) * | 2002-07-24 | 2005-04-27 | PTC Therapeutics, Inc. | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2007109107A2 (en) * | 2006-03-17 | 2007-09-27 | The Trustees Of Columbia University In The City Of New York | Atf4 as a therapeutic target in alzheimers disease and other neurological disorders |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| MX368257B (es) | 2011-08-01 | 2019-09-26 | Genentech Inc | Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer. |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| JP6806562B2 (ja) * | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｅＩＦ２α経路の調節因子 |
| KR20170027737A (ko) * | 2014-07-02 | 2017-03-10 | 인플렉티스 바이오사이언스 | O-알킬-벤질리덴구아니딘 유도체 및 미스폴딩된 단백질의 축적 관련 장애의 치료를 위한 치료 용도 |
| JP2017197433A (ja) * | 2014-09-12 | 2017-11-02 | 石原産業株式会社 | ニコチン酸エステル化合物、農園芸用殺菌剤及び植物病害の防除方法 |
| TWI763668B (zh) * | 2016-05-05 | 2022-05-11 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| CA3026982A1 (en) * | 2016-06-08 | 2017-12-14 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| WO2018225093A1 (en) * | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| US20210145771A1 (en) * | 2017-07-03 | 2021-05-20 | Glaxosmithkline Intellectual Property Development Limited | N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| UY37956A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
-
2019
- 2019-07-08 JP JP2021500661A patent/JP2021529814A/ja active Pending
- 2019-07-08 US US16/973,587 patent/US20210253528A1/en not_active Abandoned
- 2019-07-08 EP EP19770173.3A patent/EP3820843A1/en not_active Withdrawn
- 2019-07-08 CA CA3105942A patent/CA3105942A1/en active Pending
- 2019-07-08 WO PCT/IB2019/055811 patent/WO2020012339A1/en not_active Ceased
- 2019-07-08 BR BR112021000332-0A patent/BR112021000332A2/pt not_active Application Discontinuation
- 2019-07-08 CN CN201980046203.5A patent/CN112424167A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021529814A5 (https=) | ||
| JP2019521111A5 (https=) | ||
| JP2019521109A5 (https=) | ||
| RU2018146946A (ru) | Химические соединения | |
| RU2018145734A (ru) | Химические соединения в качестве ингибиторов atf4 пути | |
| JP7158382B2 (ja) | Ｃ－ｋｉｔ阻害剤としてのアミノチアゾール化合物 | |
| JP2023518286A5 (https=) | ||
| JP5978293B2 (ja) | Ｎａｍｐｔを阻害するための新規な化合物および組成物 | |
| AU2014222756B2 (en) | Inhibitors of histone demethylases | |
| CN103261160A (zh) | 用于抑制nampt的胍化合物和组合物 | |
| RU2018113430A (ru) | Производные l-фенилпирролидин-2-она в качестве ингибиторов perk | |
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| JP2022504949A5 (https=) | ||
| JP2021512059A5 (https=) | ||
| AU2018338098B2 (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
| JP2013518816A (ja) | Ｍｃｌ‐１を調節する小分子、並びに細胞死、細胞分裂、細胞分化を調節する方法、及び疾患を治療する方法。 | |
| JP2020525513A (ja) | 癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物 | |
| JP2009513703A5 (https=) | ||
| JPH11269146A (ja) | 分化誘導剤 | |
| RU2014150338A (ru) | Соединение как ингибитор передачи сигналов wnt, его композиции и применение | |
| JP2017537948A5 (https=) | ||
| US20150284347A1 (en) | New benzene sulfonamide thiazole compounds | |
| JP2020534373A5 (https=) | ||
| JP6454418B2 (ja) | ピラゾール誘導体、またはその薬理学的に許容される塩 | |
| JP2010522770A5 (https=) |